Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$17.15 - $28.31 $128,985 - $212,919
-7,521 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$19.35 - $28.41 $145,531 - $213,671
7,521 New
7,521 $214,000
Q3 2021

Nov 12, 2021

SELL
$16.88 - $25.23 $333,852 - $498,998
-19,778 Closed
0 $0
Q2 2020

Jul 22, 2020

BUY
$13.04 - $23.23 $220,154 - $392,192
16,883 Added 583.18%
19,778 $347,000
Q1 2020

Apr 20, 2020

SELL
$11.52 - $26.46 $44,444 - $102,082
-3,858 Reduced 57.13%
2,895 $43,000
Q2 2019

Aug 08, 2019

SELL
$21.48 - $27.71 $90,087 - $116,215
-4,194 Reduced 38.31%
6,753 $169,000
Q1 2019

Apr 22, 2019

BUY
$21.07 - $29.31 $230,653 - $320,856
10,947 New
10,947 $249,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.73B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Hershey Trust CO Portfolio

Follow Hershey Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hershey Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Hershey Trust CO with notifications on news.